BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1140 related articles for article (PubMed ID: 19410951)

  • 1. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.
    Sonmez K; Drenser KA; Capone A; Trese MT
    Ophthalmology; 2008 Jun; 115(6):1065-1070.e1. PubMed ID: 18031819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
    Sato T; Kusaka S; Shimojo H; Fujikado T
    Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
    Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
    Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of stromal cell-derived factor-1 in diabetic retinopathy.
    Chen LY; Zhuo YH; Li YH; Huang XH; Zhang JL; Li SY; Wang XG; Lü L
    Chin Med J (Engl); 2010 Apr; 123(8):984-8. PubMed ID: 20497701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
    Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
    Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
    Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
    Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
    Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
    Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
    Roh MI; Kim HS; Song JH; Lim JB; Kwon OW
    Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
    Brooks HL; Caballero S; Newell CK; Steinmetz RL; Watson D; Segal MS; Harrison JK; Scott EW; Grant MB
    Arch Ophthalmol; 2004 Dec; 122(12):1801-7. PubMed ID: 15596583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
    Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q; Ziemssen F; Henke-Fahle S; Tatar O; Szurman P; Aisenbrey S; Schneiderhan-Marra N; Xu X; ; Grisanti S
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.